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Abstract Themajor initial triaging decision in acute coronary
syndrome (ACS) is whether or not percutaneous coronary
intervention (PCI) is the primary treatment. Current guidelines
recommend primary PCI in ST-elevation ACS (STEACS) and
initial antithrombotic therapy in non-ST-elevation ACS
(NSTEACS). This review probes the question whether this
decision can indeed be based on the ECG. Genesis of STE/
NSTE ECGs depends on the coronary anatomy, collateral
circulation and site of the culprit lesion. Other causes than
ischaemia may also result in ST-segment changes. It has been
demonstrated that the area at risk cannot reliably be estimated
by the magnitude of the ST change, that complete as well as
incomplete occlusions can cause STE as well as NSTE ECGs,
and that STE and NSTE patterns cannot differentiate between
transmural and non-transmural ischaemia. Furthermore, un-
stable angina can occur with STE and NSTE ECGs. We
conclude that the ECG can be used to assist in detecting
ischaemia, but that electrocardiographic STE and NSTE
patterns are not uniquely related to distinctly different path-
ophysiological mechanisms. Hence, in ACS, primary PCI
might be considered regardless of the nature of the ST
deviation, and it should be done with the shortest possible
delay, because ‘time is muscle’.
Keywords Electrocardiogram . Triage . ST Elevation .
Non-ST-Elevation . Complete occlusion . Incomplete
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Introduction
There is ongoing debate concerning the difference in initial
treatment in acute coronary syndrome (ACS) between patients
presenting with and without ST-segment elevations in the
ECG [1, 2]. The guidelines state that initial treatment of
patients with ST-elevation ACS (STEACS, conventionally
called STEMI: ST-elevation myocardial infarction) is percu-
taneous coronary intervention (PCI), possibly replaced by or
preceded by thrombolysis if PCI is not or not timely available
[3]. According to the guidelines, patients with non-ST-
elevation ACS (NSTEACS, conventionally called NSTEMI:
non-ST-elevation myocardial infarction) should initially re-
ceive antithrombotic medication, and when a patient does
not have a high-risk profile, coronary angiography with or
without PCI should only be performed as a rescue procedure
after noninvasive therapy has proved to be ineffective [4, 5].
High-risk patients are defined as those with at least one of the
following features: accelerating tempo of ischaemic symp-
toms in the preceding 48 h, prolonged ongoing (>20 min) rest
pain, pulmonary oedema, new or worsening mitral regurgita-
tionmurmur, hypotension, bradycardia, tachycardia, >75 years
of age, transient ST-segment changes larger than 0.5 mm,
newly discovered bundle branch block or cardiac biomarker
elevation [4].
Stratification of ACS patients into the STE and NSTE
strata stems from the ‘thrombolysis era’ that preceded the
current ‘PCI era’. In the early 1980s, when thrombolysis
was still the predominant treatment modality, two seminal
papers were published in which the efficacy of fibrinolysis
was demonstrated in anterior myocardial infarction [6, 7].
Localisation of the ischaemia had been electrocardiographi-
cally assessed. In anterior and in ‘multiple location’ myocar-
dial infarction, hospital mortality and 1-year mortality de-
creased, while in ‘ST depression’ infarction hospital mortality
did not change significantly and 1-year mortality increased.
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Notwithstanding the incomparability of PCI and thrombolysis
as reperfusion techniques, these strata were sustained into the
PCI era, and caused the difference in preferential initial treat-
ment, invasive/noninvasive, between the STEMI andNSTEMI
groups. During the past decade, invasive rescue procedures in
NSTEACS patients have shifted from ‘late’ towards ‘early’
PCI; however, within this patient group, PCI is termed ‘early’
if performed within 24 h [8]. Within such a time span, consid-
erable necrosis may develop [9]. Also with NSTEACS, ‘time
is muscle’, and the sooner reperfusion is accomplished, the
better. Is initial waiting for success of antithrombotic treatment
in NSTEACS the optimal therapy for these patients, or should
PCI be the initial treatment in all ACS patients with persisting
signs of ischaemia at rest and no improvement after vasodilator
therapy, irrespective of the manifestation of the ECG?
In this overview, we address a number of questions related
to the role of the ECG in the first hours of ACS, including the
prehospital and the initial hospital phase. Typically, myocar-
dial salvage possibilities are largest during the ‘golden hours’
after coronary occlusion. Salvage possibilities decrease quick-
ly with time: Hedström and colleagues [9] demonstrated that,
in man, 3 h after onset of chest pain already about 25 % of the
area at risk has become necrotic.
This paper focuses on this hyperacute phase of ACS. Given
appropriate logistic conditions, this is the time frame within
which reperfusion of the occluded coronary segment can be
attained in practice. The following questions are addressed:
can the ECG, and more specifically the presence or absence of
ST elevation or non-ST elevation, contribute to:
– Diagnosis of ACS;
– Differentiation between unstable angina and ongoing
ischaemia/infarction;
– Assessment of the size of the area at risk;
– Assessment of the transmurality (transmural vs. non-
transmural) of the ischaemia;
– Assessment of the degree of occlusion of the culprit
coronary artery lesion (complete/incomplete occlusion).
The available information at first medical contact is limited
to patient history, clinical symptoms, ECG and the response to
vasodilator administration. Within the golden hours, it is often
possible to get the results of initial biomarker analysis and
echography. Hence these diagnostic options will also be ad-
dressed briefly.
– ACS diagnosis
ACS diagnosis in the hyperacute phase is mainly based on
patient history, symptoms and physical examination. The
ECG taken upon initial medical contact can be used to assist
in the decision whether the presenting symptoms are of car-
diac origin and are an expression of ACS. Typical ST-segment
changes in the ECG become manifest at a very early stage,
actually within 1 min after ischaemia onset, and even preced-
ing the onset of chest pain [10]. Despite the fact that the
sensitivity of the ECG is not high, it remains an important
tool to assist in a rapid establishment of the working diagnosis
of ACS [11, 12].
The ECG can be used to categorise ACS into STEACS or
NSTEACS. However, there are causes of STE [13–15] and of
NSTE [16] other than ischaemia / ACS. Preexisting ST-
segment abnormalities and conduction disturbancesmay ham-
per ischaemia detection in the ECG [17, 18]. On the other
hand, absence of ECG abnormalities does not exclude ACS.
Therefore, patient history remains of major importance [15].
– Differentiation between unstable angina and emerg-
ing infarction
According to the current guidelines, ACS is classified into
either STEACS or NSTEACS / unstable angina (UA)
[3–5]. UA is defined as transient ischaemia at rest with
no evidence of necrosis (no positive cardiac biomarkers or
Q waves). NSTEACS is diagnosed when also a rise in
cardiac biomarkers is detected (necrosis is detectable) [5,
19].
In our view, it is not correct to associate UA uniquely with
NSTE ECGs. Also ischaemia with STE can fade away, and
this should be termed unstable angina as well. In general,
unstable angina can occur as a consequence of the fact that
an initially occluded coronary artery spontaneously opens
in the course of ACS [20–22]. Kovacs and Yamamoto
[21] revealed that a complete coronary occlusion was
found in 90–95 % during angiography within 4 h after
onset and this fell to 50–63 % at 12–24 h after onset.
The restoration of coronary flow can be explained by
two mechanisms, namely resolution of coronary artery
vasospasm and/or the dissolution of thrombocyte aggre-
gation [19, 22].
Differentiation between unstable angina and ongoing in-
farction can only be done post hoc; at the earliest 1–3 h after
onset of ischaemia as this is the minimal time span needed to
demonstrate a detectable change in the cardiac biomarkers
[23]. Therefore, the characterisation of angina as ‘unstable’
cannot play a role in the triaging decisions in the golden hours:
appropriate treatment would be unnecessarily delayed by
waiting for eventual spontaneous resolution of the occlusion.
– Assessment of the area at risk
The magnitude of the ST changes (ΔST) is only weakly
related with the area at risk. TerHaar et al. [17] analysed ECGs
recorded during elective PCI procedures with long (till 5 min)
balloon occlusion times, data from a study done in the pre-stent
era. Actually, this setting can be regarded as a humanmodel for
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the initial minutes of acute coronary syndrome. The correlation
of the ST changes with sestamibi-assessed area-at-risk mea-
surements was low (r=0.62). This is likely to be explained by
the cancellation effect, due to which small changes in the ST
segment can occur in the presence of relatively large areas at
risk. A large, curved ischaemic area can thus cause a small ST-
amplitude change on the ECG. In conclusion, the size of the
ST change does not give a reasonably accurate estimation of
the size of the area at risk. Birnbaum et al. [24] mention, as an
example, the proximal occlusion of a dominant left circumflex
artery before the first obtuse marginal branch. This will cause
transmural ischaemia of both the basal, mid-anterolateral, and
inferior regions and may result in only minimal ST deviations
in the limb leads.
– Assessment of the transmurality of the ischaemia
It is generally assumed that STEACS is associated with
transmural ischaemia whereas NSTEACS is mostly associat-
ed with non-transmural subendocardial ischaemia [24].
Sarafoff and colleagues [12] quantified size and transmural
extent of the infarcted area by contrast-enhanced cardiac mag-
netic resonance imaging in 220 patients and compared this
with their admission ECG (57% had STEECGs and 43% had
NSTE ECGs). The infarction was transmural in 63 % of the
STEACS patients and in 27 % of the NSTEACS patients.
Because necrotic tissue (infarcted area) was measured in this
study, the ischaemic area / area at risk in the hyperacute phase
of ACS has extended further. Hence, the assumption that STE/
NSTE ECGs represent transmural/non-transmural ischaemia
is therefore incorrect, the difference is more gradual.
NSTEACS may be associated with a smaller percentage of
transmural ischaemia than STEACS; however, with 27 % of
the patients having transmural ischaemia this is still a signif-
icant number of patients.
– Assessment of the degree of occlusion
Some publications suggest that STE and NSTE ECGs are
caused by complete, prolonged and by incomplete, temporal
occlusions of a coronary artery segment, respectively [25–27].
The current guidelines [4] state that NSTE ECGs can occur
with complete and with incomplete occlusion. In contrast, the
current STEACS guidelines do not make this distinction [3].
Several studies have shown that complete and incomplete
occlusion can produce STE as well as NSTE ECGs. Studying
a series of 300 ACS patients with a completely occluded
culprit artery and treated by primary PCI, it was found that
28.7 % of these patients had an NSTE ECG [28]. Study-
ing NSTEACS patients, Wang et al. [29] and Bahrmann
et al. [30] report occluded (Thrombolysis in Myocardial
Infarction flow grade 0 to 1) culprit arteries in 27 and
29 % of the patients, respectively. Occlusions were more
often found in coronary arteries supplying the inferolateral
or posterolateral myocardium; patients with an occluded cul-
prit artery had larger infarcts and a higher 6-month mortality
[29, 30]. Knot et al. [26] found that the infarct-related artery
was occluded in 66 % of the STEACS patients and in 35 % of
NSTEACS patients with an ST-depression ECG (ST depres-
sion was defined as ‘new horizontal or down-sloping ST
depression≥0.05 mV in two contiguous leads or transient
ST-segment elevations’). Koyama et al. [31] found occluded
culprit arteries in 60% of the STEACS patients and in 51% of
the NSTEACS patients. The prevalence of coronary flow
limitation in NSTEACS patients was almost as high as in
STEACS patients. In their study, Koyama and colleagues
applied an acute PCI procedure treatment strategy to ‘all
patients with non-ST elevation acute coronary syndromes if
symptoms and/or electrocardiographic abnormalities did not
respond to anti-ischaemic treatment within 20 min and acute
myocardial infarction (AMI) was suspected by clinicians.’
Using this treatment strategy, they achieved an average
treatment delay, calculated from onset of symptoms, of 203
and 292 min in the STE and NSTE patients, respectively.
Ter Haar and colleagues [17] analysed a database of ECGs
taken during long balloon occlusions in elective percutaneous
transluminal coronary angioplasty procedures. Occlusion sites
were the left main coronary artery (2 %), left anterior descend-
ing (30 %), right coronary artery (49 %), and left circumflex
(19 %). After 3 min of complete occlusion, 55 % of the
patients had an STE ECG and 45 % had an NSTE ECG. This
demonstrates directly how occlusions at various locations in
the coronary arterial system may cause STE as well as NSTE
ECGs.
In conclusion, both complete and incomplete coronary
artery occlusions can cause both STE and NSTE ECGs and,
hence, STE and NSTE ECGs do not discriminate complete
and incomplete coronary artery occlusions.
– Early biomarker analysis
Guidelines state that the diagnosis of myocardial infarc-
tion is based on a rise in cardiac biomarker concentrations,
demonstrating necrosis [3, 4]. Van der Laarse et al.(23)
describe that determining cardiac troponin I/T in the hy-
peracute phase of ACS is not yet sensitive enough.
Sebbane et al. [32] and Afzali et al. [33] revealed that the
detection of the combination of troponin and copeptin
could be used to rule out NSTEACS and could help iden-
tify which patients were suitable for discharge (sensitivity
increased from 76 % (troponin alone) to 96 % (combina-
tion of troponin and copeptin)). Charpentier et al. [34]
stated that the measurement of the combination of troponin
and copeptin improved the diagnostic accuracy for
NSTEACS patients, but the sensitivity (90.4 %) was too
low to rule out NSTEACS.
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Irrespective of the diagnostic modality, it takes at
least 1–3 h after the onset of symptoms to detect such
a rise and, actually, waiting this long before the deci-
sion to perform PCI is taken implies that already sub-
stantial damage to the myocardium may occur [23].
Concluding, the early measurement of cardiac bio-
markers is not sensitive enough to diagnose emerging
infarction in the initial stage of ischaemia, and waiting
for a demonstrable rise in biomarkers creates an unaccept-
able time delay.
– Echocardiography
In the ischaemic cascade, mechanical dysfunction pre-
cedes electrical dysfunction and angina [10]. Echocardiog-
raphy is generally accessible in the emergency department
and can help to diagnose ACS; this is especially useful
when the ECG is inconclusive [35]. In an early study in the
Netherlands, Peels and colleagues reported, with two-
dimensional echocardiography, 92 % sensitivity, 53 % spec-
ificity and 94 % negative predictive accuracy in patients
admitted to the emergency department with acute chest
pain and a non-diagnostic ECG [36].
Discussion
Angioplasty to restore coronary blood flow was first per-
formed in an elective procedure by Gruentzig in 1977 [37].
Soon thereafter, the first reports appeared describing the re-
sults of angioplasty in acute myocardial infarction patients
[38, 39]. In the early 1980s thrombolysis was still the pre-
dominant treatment modality, and in 1986 and 1987 two
seminal papers appeared in which the efficacy of fibrinolysis
was demonstrated in anterior myocardial infarction [6, 7].
Localisation of the ischaemia had been electrocardiographi-
cally assessed. In anterior myocardial infarction hospital mor-
tality decreased from 18.4 % (saline infusion, control) to
14.5 % (streptokinase infusion); 1-year mortality decreased
from 26.0 to 22.1 %. In ‘multiple location’ infarction, hospital
mortality decreased from 13.9 to 9.0 % and 1-year mortality
decreased from 17.9 to 14.4 %. In ‘ST depression’ infarction,
hospital mortality did not change significantly and 1-year
mortality increased from 24.2 to 34.0 %. From then on, the
leading thought emerged that reperfusion attempts were ben-
eficial in anterior myocardial infarction and were detrimental
in ‘ST depression’myocardial infarction, where antithrombot-
ic treatment became the predominating initial therapy. Not-
withstanding the incomparability of PCI and thrombolysis as
reperfusion techniques, this concept has sustained into the PCI
era, and this explains why there is little evidence about the
efficacy of primary PCI in NSTEACS.
Whether a patient will develop an STE or an NSTE ECG
during ischaemia depends on the location of the culprit lesion
and on the existence and extent of collaterals. Menon and
colleagues [40] and Wong and colleagues [41] demonstrated
that occlusion of the circumflex coronary artery occurs more
often in NSTE ECGs (42.5 %) than in STE ECGs (11.2 %).
The development of collaterals determines the extent of
ischaemia and this can have either unexpected severe or
irrelevant effects. Bahrmann et al. [30] showed that well-
developed collaterals can limit the extent of myocardial
damage and can improve the clinical outcome of the
patient [42]. However, the existence of collaterals can also
determine the extent of ischaemia in a negative manner in
cases where the occlusion reduces the blood flow to the
area supplied by the collaterals [43]. These considerations
underline that there is no simple way to separate STEACS
and NSTEACS patients; the underlying and sometimes
individually very different anatomy of the coronary artery
tree and the collateral circulation can create overlapping
electrocardiographic manifestations.
In ACS, the prevalence of NSTEACS is higher (60 %)
than STEACS (40 %).(44) The average characteristics of
STEACS and NSTEACS patients differ. NSTEACS patients
are in general 4 years older, more often female and more
often have multivessel disease (41.1 % vs. 29.9 %);
STEACS patients are more often haemodynamically unstable
at presentation [44, 45].
The most recent NSTEACS guidelines [46] state that
immediate PCI in NSTEACS patients has no advantages
but also no disadvantages for the patients. The evidence
for this statement is, however, limited: it is based on a
single investigation, in which the outcome was based on
the peak troponin level [47]. Some reports have been
published about the experience with primary PCI in
NSTEACS patients, and compared the results with those
in STEACS patients [1, 26, 29, 31]. (Knot et al. [26]
restricted the NSTEACS group to patients with ST
depression). The results suggest that primary PCI in
NSTEACS patients is recommendable. Katritsis et al.
[48] demonstrated that PCI soon after admission of
NSTEACS patients significantly reduced the risk for
recurrent ischaemia (relative risk 0.59) and the duration
of hospital stay (by 28 %). Furthermore, there was a
decrease in major bleeding events (relative risk 0.78) and
less death, MI or stroke (relative risk 0.91). Birnbaum and
colleagues [11, 49] recently compiled a number of NSTE
patterns (patterns associated with ongoing ischaemia or with
reperfusion), which would require revascularisation by PCI
because of the associated high risk.
Birnbaum et al. [24] provide an overview of the many
similarities between the pathology underlying STE and NSTE
ECGs and explain the physical concepts underlying the gen-
esis of the ECG and why ischaemia at certain locations
Neth Heart J (2014) 22:484–490 487
manifests with STE and at other locations manifests as NSTE.
This view has partly been adopted by current clinical practice,
because ‘true’ lateral (formerly termed posterior) ischaemia
that manifests as ST depression in leads V1 through V3 is now
called and treated as STEACS.
The size of the infarct is important for the prognosis after
the initial treatment of ACS [9]. Coronary artery disease is the
most common cause of heart failure (HF, in 50–70 % of the
cases) [50]. Also smaller infarctions can lead to heart failure
[3, 51]. Goel et al. [50] showed that every 1-h delay in
performing PCI is associated with 4–12 % increased risk of
new-onset heart failure and a 4 % relative increase in the risk
of incident heart failure during follow-up. This research un-
derscores the urgency to decide about the initial treatment
strategy in NSTEACS.
In evidence-based medicine, decisions about the optimal
treatment of patients are taken on the basis of their risk
stratification. In ACS, the hazard of maintaining the STEACS
and NSTEACS strata originating from the pre-PCI era is that
NSTEACS patients have delayed access to PCI. This can lead
to unnecessarily large necrotic areas, with negative conse-
quences for the prognosis of these patients.
If, in addition to STEACS patients, also NSTEACS
patients were to be candidates for primary PCI, this
would grossly increase the amount of emergency
catheterisations. It is difficult to predict the economic
consequences of such a dramatic change in treatment
strategy. On one hand, it is known that PCI treatment is
expensive, especially in NSTE patients [52]. On the
other hand, rescue PCI in NSTE patients is often per-
formed late, up to 24 h after start of the symptoms,
sometimes after transportation from a non-PCI equipped
hospital to a hospital with PCI facilities. These condi-
tions together may partly explain the increased costs.
Swift primary PCI in these patients might make the
costs more comparable with those of the STE PCI
patients and might considerably change the further
course of the emerging infarction scar and the associated
cardiac function, and have influences on both the current
hospital stay and on the long-term prognosis of this patient.
If swift emergency PCI is the best way to treat these patients,
the associated costs would be more likely to decrease than
increase.
Actually, adopting primary PCI as the treatment of choice
in STEACS as well as in NSTEACS creates a new stratum of
patients in whom the optimal treatment strategies are still to be
established. An initial important choice would be the selection
of the type of stent to be used in the primary PCI procedure.
Comparisons made between drug-eluting stents in STE and
NSTE patients, such as the everolimus-sirolimus comparison
study by Velders et al., [53] have to be repeated for this new
stratum. Also, the medication regimen in this patient group
should be reconsidered.
With the vanishing STE / NSTE classification, the direction
of the ischaemia vector in the ECG is no longer relevant.
Instead, measuring the ischaemia vector size, or a surrogate
measure thereof, as proposed by Meissner and colleagues
[54], would be more appropriate. For sufficient sensitivity
the detection threshold for ischaemia in the STsegment should
be lower than the current values of 0.1 mV; possibly this
should go down to 0.05 or even 0.025 mV [18]. Such a low
detection threshold is difficult to apply in the many patients
who have preexisting non-zero ST segments or conduction
defects. Also, it would fail, as do the current criteria, in
patients with preexisting conduction disturbances / wide
QRS complexes. This intrinsic problem in ischaemia detec-
tion in the ECG can be addressed by serial ECG analysis
(comparison of the acute ECG with a previous ECG of the
same patient that serves as a baseline ECG) [17, 18, 55].
In conclusion, and summarized in Fig. 1, electrocardio-
graphic STE and NSTE patterns are not uniquely related to
distinctly different pathophysiological mechanisms; in our
view, prompt PCI should be considered in all ACS patients,
irrespective of whether ischaemia manifests as STE or as
NSTE.
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Fig. 1 STE and NSTE acute coronary syndrome (STEACS and
NSTEACS) are syndromes without a sharp contrast: properties overlap
and differences are gradual. Prevalence: NSTEACS occurs slightly more
often than STEACS [44]; multivessel disease: NSTEACS patients have
slightly more often multivessel disease [44]; infarct-related artery
occluded: this occurs more often in STEACS patients but also in a
considerable percentage of NSTEACS patients [26, 28–31]; transmural
infarction: this occurs more often in STEACS patients but also in a
considerable percentage of NSTEACS patients [12]; ECG after 3 min
of balloon occlusion: in elective PCI, only a slight majority of ECGs after
3 min of complete occlusion shows ST elevation [17]
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